NEW YORK (
CHANGE IN RATINGS
upgraded at Sterne Agee from Neutral to Buy. $42 price target. Stabilizing ISM-PMU in US-China into 1H12.
Cliffs Natural Resources
rated new Outperform at Credit Suisse. $90 price target. Cheap relative to US metal peers.
Community Health Systems
rated new Market Perform at BMO Capital Markets. $20 price target. Pressure on hospital fundamentals.
rated new Hold at KeyBanc. Limited upside potential near term.
(GES - Get Report)
downgraded at Citigroup from Buy to Neutral, Citigroup said. $33 price target. 3Q came with a double digit drop in its retail comp in Europe.
Health Management Associates
rated new Market Perform at BMO Capital Markets. $9 price target. Innovation improves outlook but many obstacles remain.
(LOW - Get Report)
upgraded at Goldman from Neutral to Buy. $28 price target. Management is embracing the need for meaningful upgrades after years of drift.
rated new Market Perform at BMO Capital Market. $39 price target. Pointed in the right direction but fully valued.
(LULU - Get Report)
upgraded at KeyBanc from Underweight to Buy. $58 price target. Higher in-stock levels will drive sustained profit growth in 2012.
downgraded at Goldman from Buy to Neutral. $97 price target. Recent share outperformance.
Sun Life Financial
upgraded at Morgan Stanley from Underweight to Equal-weight. Meaningful recent underperformance.
(THC - Get Report)
rated new Market Perform at BMO Capital Markets. $5 price target. Current valuation leaves little room for appreciation.
Universal Health Services
rated new Outperform at BMO Capital Markets. $47 price target. Stronger more diversified earnings engine.
upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $20.50 target price. Selloff following Seaway pipeline reversal announcement is overdone.
STOCK COMMENTS / EPS CHANGES
Affiliated Managers Group
(AMG - Get Report)
target raised at Jefferies to $107. Pipeline growth accelerating. Buy rating.
(AVGO - Get Report)
numbers lowered at Jefferies DEC 02, 2011 | 7:40 AM EST Shares of AVGO now seen reaching $41, Jefferies said. Estimates also lowered on slow demand out of China. Buy rating.
(HCA - Get Report)
rated new Market Perform at BMO Capital Market. $27 price target. Strong copany but leverage limits upside.